Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Xoma Royalty Corporation (NQ: XOMA ) 27.60 -0.99 (-3.46%) Streaming Delayed Price Updated: 12:23 PM EDT, Jul 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 10,211 Open 28.00 Bid (Size) 27.66 (1) Ask (Size) 28.48 (1) Prev. Close 28.59 Today's Range 27.07 - 28.50 52wk Range 13.48 - 29.00 Shares Outstanding 11,625,826 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base July 09, 2024 FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. Via Benzinga Exposures Product Safety Demystifying XOMA: Insights From 5 Analyst Reviews July 09, 2024 Via Benzinga Performance YTD +32.12% +32.12% 1 Month +6.85% +6.85% 3 Month +6.89% +6.89% 6 Month +35.29% +35.29% 1 Year +73.69% +73.69% More News Read More XOMA Declares Quarterly Preferred Stock Dividends June 20, 2024 From XOMA Corporation Via GlobeNewswire XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher June 12, 2024 From XOMA Corporation Via GlobeNewswire Peeling Back The Layers: Exploring XOMA Through Analyst Insights May 31, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For XOMA April 29, 2024 Via Benzinga Recap: XOMA Q4 Earnings March 08, 2024 Via Benzinga 3 Crazy Good Stocks to Buy With $500 Right Now June 12, 2024 Via InvestorPlace XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ May 14, 2024 From XOMA Corporation Via GlobeNewswire XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities May 09, 2024 From XOMA Corporation Via GlobeNewswire XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% April 30, 2024 From XOMA Corporation Via GlobeNewswire XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) April 25, 2024 From XOMA Corporation Via GlobeNewswire XOMA Corporation Announces Closing of Tender Offer April 03, 2024 From XOMA Corporation Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE) March 25, 2024 From Brodsky & Smith LLC Via GlobeNewswire XOMA Declares Quarterly Preferred Stock Dividends March 21, 2024 From XOMA Corporation Via GlobeNewswire XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. March 19, 2024 From XOMA Corporation Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – March 19, 2024 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB) March 13, 2024 From Brodsky & Smith LLC Via GlobeNewswire XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 March 08, 2024 Via InvestorPlace XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value March 08, 2024 From XOMA Corporation Via GlobeNewswire XOMA to Present at Upcoming Investor Conferences in March February 28, 2024 From XOMA Corporation Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB) February 20, 2024 From Brodsky & Smith LLC Via GlobeNewswire Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma February 16, 2024 Via Benzinga XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right February 16, 2024 From XOMA Corporation Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
